Erratum: Increased expression of Lgr5 is associated with chemotherapy resistance in human gastric cancer (Oncol Rep (2014) 32(181-188)Doi:10.3892/or.2014.3207);Increased expression of Lgr5 is associated with chemotherapy resistance in human gastric cancer

Oncology Reports

Volumn 32, Issue 1, 2014, Pages 181-188

  Xi, Hong Qing ^a   Cui, Jian Xin ^a   Shen, Wei Song ^a   Wu, Xiao Song ^a   Bian, Shi B O ^a   Li, J I Yang ^a   Song, Zhou ^a   Wei, B O ^a   Chen, Lin ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Chemoresistance; Gastric cancer; Lgr5; Prognosis

Indexed keywords

FLUOROURACIL; FOLINIC ACID; G PROTEIN COUPLED RECEPTOR; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; LEUCINE RICH REPEAT CONTAINING G PROTEIN COUPLED RECEPTOR 5; MESSENGER RNA; OXALIPLATIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; LGR5 PROTEIN, HUMAN;

ADJUVANT THERAPY; ADULT; ADVANCED CANCER; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER REGRESSION; CANCER RESISTANCE; CELL LEVEL; CELL VIABILITY; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG SENSITIVITY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE; STOMACH CANCER; SURVIVAL PREDICTION; SURVIVAL TIME; AGED; DRUG EFFECTS; DRUG RESISTANCE; METABOLISM; MULTIVARIATE ANALYSIS; PATHOLOGY; PROGNOSIS; STOMACH NEOPLASMS; SURVIVAL; TREATMENT OUTCOME; TUMOR CELL LINE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; RECEPTORS, G-PROTEIN-COUPLED; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84903127141     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2019.7120     Document Type: Erratum

References (40)

1. Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108, 2005. (Pubitemid 40372904)
2. Thun MJ, DeLancey JO, Center MM, Jemal A and Ward EM: The global burden of cancer: priorities for prevention. Carcinogenesis 31: 100-110, 2010.
3. Cunningham D, Allum WH, Stenning SP, et al: Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355: 11-20, 2006.
4. Becker K, Langer R, Reim D, et al: Significance of histopathological tumor regression after neoadjuvant chemotherapy in gastric adenocarcinomas: a summary of 480 cases. Ann Surg 253: 934-939, 2011.
5. Van der Flier LG, Sabates-Bellver J, Oving I, et al: The intestinal Wnt/TCF signature. Gastroenterology 132: 628-632, 2007.
6. Segditsas S, Sieber O, Deheragoda M, et al: Putative direct and indirect Wnt targets identified through consistent gene expression changes in APC-mutant intestinal adenomas from humans and mice. Hum Mol Genet 17: 3864-3875, 2008. (Pubitemid 352762849)
7. Yamamoto Y, Sakamoto M, Fujii G, et al: Overexpression of orphan G-protein-coupled receptor, Gpr49, in human hepatocellular carcinomas with beta-catenin mutations. Hepatology 37: 528-533, 2003. (Pubitemid 36258773)
8. Carmon KS, Lin Q, Gong X, Thomas A and Liu Q: LGR5 interacts and cointernalizes with Wnt receptors to modulate Wnt/β-catenin signaling. Mol Cell Biol 32: 2054-2064, 2012.
9. Barker N, van Es JH, Kuipers J, et al: Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature 449: 1003-1007, 2007. (Pubitemid 350014593)
10. Jaks V, Barker N, Kasper M, et al: Lgr5 marks cycling, yet long-lived, hair follicle stem cells. Nat Genet 40: 1291-1299, 2008.
11. Barker N, Huch M, Kujala P, et al: Lgr5(+ve) stem cells drive self-renewal in the stomach and build long-lived gastric units in vitro. Cell Stem Cell 6: 25-36, 2010.
12. + cells correlates with gastric cancer progression. PLoS One 7: e35486, 2012.
13. Takahashi H, Ishii H, Nishida N, et al: Significance of Lgr5(+ve) cancer stem cells in the colon and rectum. Ann Surg Oncol 18: 1166-1174, 2011.
14. Kemper K, Prasetyanti PR, De Lau W, Rodermond H, Clevers H and Medema JP: Monoclonal antibodies against Lgr5 identify human colorectal cancer stem cells. Stem Cells 30: 2378-2386, 2012.
15. Wu XS, Xi HQ and Chen L: Lgr5 is a potential marker of colorectal carcinoma stem cells that correlates with patient survival. World J Surg Oncol 10: 244, 2012.
16. McClanahan T, Koseoglu S, Smith K, et al: Identification of overexpression of orphan G protein-coupled receptor GPR49 in human colon and ovarian primary tumors. Cancer Biol Ther 5: 419-426, 2006.
17. Tanese K, Fukuma M, Yamada T, et al: G-protein-coupled receptor GPR49 is up-regulated in basal cell carcinoma and promotes cell proliferation and tumor formation. Am J Pathol 173: 835-843, 2008.
18. Becker L, Huang Q and Mashimo H: Lgr5, an intestinal stem cell marker, is abnormally expressed in Barrett's esophagus and esophageal adenocarcinoma. Dis Esophagus 23: 168-174, 2010.
19. Nakata S, Campos B, Bageritz J, et al: LGR5 is a marker of poor prognosis in glioblastoma and is required for survival of brain cancer stem-like cells. Brain Pathol 23: 60-72, 2013.
20. Vermeulen L, Todaro M, de Sousa Mello F, et al: Single-cell cloning of colon cancer stem cells reveals a multi-lineage differentiation capacity. Proc Natl Acad Sci USA 105: 13427-13432, 2008.
21. Becker L, Huang Q and Mashimo H: Immunostaining of Lgr5, an intestinal stem cell marker, in normal and premalignant human gastrointestinal tissue. ScientificWorldJournal 8: 1168-1176, 2008.
22. Saigusa S, Inoue Y, Tanaka K, et al: Clinical significance of LGR5 and CD44 expression in locally advanced rectal cancer after preoperative chemoradiotherapy. Int J Oncol 41: 1643-1652, 2012.
23. Saigusa S, Inoue Y, Tanaka K, et al: Significant correlation between LKB1 and LGR5 gene expression and the association with poor recurrence-free survival in rectal cancer after preoperative chemoradiotherapy. J Cancer Res Clin Oncol 139: 131-138, 2013.
24. Ozkan M, Akbudak IH, Deniz K, et al: Prognostic value of excision repair cross-complementing gene 1 expression for cisplatin-based chemotherapy in advanced gastric cancer. Asian Pac J Cancer Prev 11: 181-185, 2010.
25. Oken MM, Creech RH, Tormey DC, et al: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5: 649-655, 1982. (Pubitemid 13149996)
26. Becker K, Mueller JD, Schulmacher C, et al: Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer 98: 1521-1530, 2003. (Pubitemid 37151509)
27. Xi HQ, Wu XS, Wei B and Chen L: Aberrant expression of EphA3 in gastric carcinoma: correlation with tumor angiogenesis and survival. J Gastroenterol 47: 785-794, 2012.
28. Xi HQ, Zhao P and Han WD: Clinicopathological significance and prognostic value of LRP16 expression in colorectal carcinoma. World J Gastroenterol 16: 1644-1648, 2010.
29. Matsubara J, Yamada Y, Nakajima TE, et al: Clinical significance of insulin-like growth factor type 1 receptor and epidermal growth factor receptor in patients with advanced gastric cancer. Oncology 74: 76-83, 2008. (Pubitemid 351915013)
30. Wood LD, Calhoun ES, Silliman N, et al: Somatic mutations of GUCY2F, EPHA3, and NTRK3 in human cancers. Hum Mutat 27: 1060-1061, 2006.
31. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method. Methods 25: 402-408, 2001. (Pubitemid 34164012)
32. Lordick F, Stein HJ, Peschel C and Siewert JR: Neoadjuvant therapy for oesophagogastric cancer. Br J Surg 91: 540-551, 2004. (Pubitemid 38624660)
33. Al-Hajj M: Cancer stem cells and oncology therapeutics. Curr Opin Oncol 19: 61-64, 2007.
34. Dirks PB: Cancer: stem cells and brain tumours. Nature 444: 687-688, 2006.
35. Setoguchi T, Taga T and Kondo T: Cancer stem cells persist in many cancer cell lines. Cell Cycle 3: 414-415, 2004. (Pubitemid 40278224)
36. Haq R and Zanke B: Inhibition of apoptotic signaling pathways in cancer cells as a mechanism of chemotherapy resistance. Cancer Metastasis Rev 17: 233-239, 1998. (Pubitemid 28391958)
37. Gu L, Findley HW, Zhu N and Zhou M: Endogenous TNFalpha mediates cell survival and chemotherapy resistance by activating the PI3K/Akt pathway in acute lymphoblastic leukemia cells. Leukemia 20: 900-904, 2006.
38. Mahon KL, Henshall SM, Sutherland RL and Horvath LG: Pathways of chemotherapy resistance in castration-resistant prostate cancer. Endocr Relat Cancer 18: R103-R123, 2011.
39. Cui J, Jiang W, Wang S, Wang L and Xie K: Role of Wnt/β-catenin signaling in drug resistance of pancreatic cancer. Curr Pharm Des 18: 2464-2471, 2012.
40. Zhang H, Zhang X, Wu X, et al: Interference of Frizzled 1 (FZD1) reverses multidrug resistance in breast cancer cells through the Wnt/β-catenin pathway. Cancer Lett 323: 106-113, 2012.